Yet the use of lower doses of IL-2, with the underlying rationale that Treg cells would be more efficiently targeted than effector T cells, showed a preferential expansion of Treg cells both in preclinical models and in type 1 diabetes patients, which was associated with better prognostic markers54,55. This evidence concerns the gene IL2 and type 1 diabetes mellitus.